Abstract
Abstract We evaluated the clinical outcomes and relapse patterns of 80 patients with primary sinonasal tract diffuse large B-cell lymphoma (SN-DLBCL) treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) chemotherapy at 22 institutions. A total of 59 (73.8%) patients received R-CHOP chemotherapy alone, whereas 21 (26.3%) were treated with R-CHOP followed by involved field radiotherapy (IFRT). In 73 patients with Ann Arbor stage I-II disease, no significant difference was found in the response rate or overall survival (OS) between R-CHOP alone (n = 52) and R-CHOP followed by IFRT (n = 21). Among 11 relapsed patients in this study, the most common pattern of relapse was local (n = 8, 11.8%), whereas central nervous system (CNS) relapse was observed in only one (1.9%) patient. These results suggest that patients with primary SN-DLBCL treated with R-CHOP have a relatively low CNS relapse rate and better OS compared to previous studies before the introduction of R.
| Original language | English |
|---|---|
| Pages (from-to) | 1020-1026 |
| Number of pages | 7 |
| Journal | Leukemia and Lymphoma |
| Volume | 56 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2015 Apr 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Hematology
- Oncology
- Cancer Research
Cite this
}
Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy : A study by the Consortium for Improving Survival of Lymphoma. / Consortium for Improving Survival of Lymphoma (CISL) study group.
In: Leukemia and Lymphoma, Vol. 56, No. 4, 01.04.2015, p. 1020-1026.Research output: Contribution to journal › Article
TY - JOUR
T1 - Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy
T2 - A study by the Consortium for Improving Survival of Lymphoma
AU - Consortium for Improving Survival of Lymphoma (CISL) study group
AU - Lee, Gyeong Won
AU - Go, Se Il
AU - Kim, Seok Hyun
AU - Hong, Junshik
AU - Kim, Yu Ri
AU - Oh, Sukjoong
AU - Kim, Sung Yong
AU - Do, Young Rok
AU - Lee, Hyewon
AU - Lee, Soon Il
AU - Bae, Sung Hwa
AU - Oh, Sung Yong
AU - Song, Moo Kon
AU - Lee, Won Sik
AU - Lee, Bohee
AU - Kim, Jinseok
AU - Kim, Min Kyoung
AU - Kang, Hye Jin
AU - Ahn, Jae Sook
AU - Yhim, Ho Young
AU - Kim, Hyo Jung
AU - Kim, Seok Jin
AU - Kim, Won Seog
AU - Suh, Cheolwon
PY - 2015/4/1
Y1 - 2015/4/1
N2 - Abstract We evaluated the clinical outcomes and relapse patterns of 80 patients with primary sinonasal tract diffuse large B-cell lymphoma (SN-DLBCL) treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) chemotherapy at 22 institutions. A total of 59 (73.8%) patients received R-CHOP chemotherapy alone, whereas 21 (26.3%) were treated with R-CHOP followed by involved field radiotherapy (IFRT). In 73 patients with Ann Arbor stage I-II disease, no significant difference was found in the response rate or overall survival (OS) between R-CHOP alone (n = 52) and R-CHOP followed by IFRT (n = 21). Among 11 relapsed patients in this study, the most common pattern of relapse was local (n = 8, 11.8%), whereas central nervous system (CNS) relapse was observed in only one (1.9%) patient. These results suggest that patients with primary SN-DLBCL treated with R-CHOP have a relatively low CNS relapse rate and better OS compared to previous studies before the introduction of R.
AB - Abstract We evaluated the clinical outcomes and relapse patterns of 80 patients with primary sinonasal tract diffuse large B-cell lymphoma (SN-DLBCL) treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) chemotherapy at 22 institutions. A total of 59 (73.8%) patients received R-CHOP chemotherapy alone, whereas 21 (26.3%) were treated with R-CHOP followed by involved field radiotherapy (IFRT). In 73 patients with Ann Arbor stage I-II disease, no significant difference was found in the response rate or overall survival (OS) between R-CHOP alone (n = 52) and R-CHOP followed by IFRT (n = 21). Among 11 relapsed patients in this study, the most common pattern of relapse was local (n = 8, 11.8%), whereas central nervous system (CNS) relapse was observed in only one (1.9%) patient. These results suggest that patients with primary SN-DLBCL treated with R-CHOP have a relatively low CNS relapse rate and better OS compared to previous studies before the introduction of R.
UR - http://www.scopus.com/inward/record.url?scp=84929077148&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84929077148&partnerID=8YFLogxK
U2 - 10.3109/10428194.2014.946027
DO - 10.3109/10428194.2014.946027
M3 - Article
C2 - 25039351
AN - SCOPUS:84929077148
VL - 56
SP - 1020
EP - 1026
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
SN - 1042-8194
IS - 4
ER -